Facebook Pixel Focusing on VIGILANCE & PREPAREDNESS | BioSpectrum Asia - Business - इस कहानी को Magzter.com पर पढ़ें

कोशिश गोल्ड - मुक्त

Focusing on VIGILANCE & PREPAREDNESS

BioSpectrum Asia

|

BioSpectrum Asia Dec 2021

Despite advances in development of countermeasures such as diagnostics, therapeutics and vaccines, world travel and increased global interdependence have added layers of complexity to containing infectious diseases.

- Dr Manbeena Chawla

Focusing on VIGILANCE & PREPAREDNESS

COVID-19, an outcome of weaponisation by genetic manipulation as part of ‘gain of function’ research, had brought the entire world to its knees in less than six months. Now, researchers and policymakers are being more vigilant towards surveillance and management of emerging infectious disease threats, and revisit global mechanisms for the control of pandemic disease. In addition to other countries across the globe, 2021 saw many initiatives taken by the APAC region to strengthen their capacities for effective preparedness and for the prevention of new and existing infectious diseases.

Infectious diseases have been increasing in frequency during the past few decades. These include recurring outbreaks caused by influenza and Ebola viruses; diseases that have dramatically increased their range and impact such as Chikungunya and Zika viruses; and outbreaks caused by novel pathogens such as severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) in 2002 and SARS-CoV-2 in 2019–20, the virus responsible for the current COVID-19 pandemic.

A section of experts attribute this to unlawful and potentially dangerous ‘gain of function’ research which, among other reasons, looks to ‘weaponise’ the naturally occurring viruses. More recently, Bill Gates announced the successful development of a vaccine against smallpox (a disease already eradicated) in the (un)likely event of a bioterror attack using the smallpox virus. The unprecedented scale and rapidity of dissemination of recent emerging infectious diseases pose new challenges for vaccine developers, regulators, health authorities and political constituencies.

BioSpectrum Asia

यह कहानी BioSpectrum Asia के BioSpectrum Asia Dec 2021 संस्करण से ली गई है।

हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।

क्या आप पहले से ही ग्राहक हैं?

BioSpectrum Asia से और कहानियाँ

BioSpectrum Asia

BioSpectrum Asia

Alphamab Oncology appoints Fei Wang as Chief Financial Officer

Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market

DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

PHCbi introduces LiCellGrow Cell Expansion System

PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences

CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala

Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Argo Biopharma ropes in Dr Gena Wang as CFO and CSO

China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust

The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Korea designs model for accurate and scalable drug-drug interaction prediction

A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.

time to read

1 min

BioSpectrum Asia April 2027

Translate

Share

-
+

Change font size